About Transcription factor E2F4
Transcription factor E2F4 (E2F4) is a protein
from Homo sapiens identified by UniProt accession
Q16254, 413 residues long.
MolForge cross-references it against 0 known binders and
217 disease associations.
Target properties
| Protein name | Transcription factor E2F4 |
|---|
| UniProt accession | Q16254 |
|---|
| Gene | E2F4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 413 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (217)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.61
- mean corpuscular hemoglobin · score 0.57
- mean reticulocyte volume · score 0.54
- head and neck squamous cell carcinoma · score 0.28
- glioblastoma multiforme · score 0.27
- endometrial cancer · score 0.27
- coronary artery disease · score 0.26
- breast adenocarcinoma · score 0.25
- urinary bladder cancer · score 0.23
- hematological measurement · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q16254-F1 | alphafold | PREDICTED | 64.20 | — |
Amino-acid sequence (413 residues)
MAEAGPQAPP PPGTPSRHEK SLGLLTTKFV SLLQEAKDGV LDLKLAADTL AVRQKRRIYD ITNVLEGIGL IEKKSKNSIQ WKGVGPGCNT REIADKLIEL KAEIEELQQR EQELDQHKVW VQQSIRNVTE DVQNSCLAYV THEDICRCFA GDTLLAIRAP SGTSLEVPIP EGLNGQKKYQ IHLKSVSGPI EVLLVNKEAW SSPPVAVPVP PPEDLLQSPS AVSTPPPLPK PALAQSQEAS RPNSPQLTPT AVPGSAEVQG MAGPAAEITV SGGPGTDSKD SGELSSLPLG PTTLDTRPLQ SSALLDSSSS SSSSSSSSSN SNSSSSSGPN PSTSFEPIKA DPTGVLELPK ELSEIFDPTR ECMSSELLEE LMSSEVFAPL LRLSPPPGDH DYIYNLDESE GVCDLFDVPV LNL
Explore Transcription factor E2F4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets